ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Durvalumab is on this study

  • The record lists it as a treatment, written “Durvalumab (Imfinzi) immunotherapy”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 3, 2026, 2:43 AM UTC“With tremelimumab after TheraSphere in liver cancer”
  • The role rule says the same.
  • So Durvalumab's page lists this study under “Testing it”.
13 links1 made here, not in the record15 judgments2 judges (the rules as one: Rule based)2 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT05063565TheraSphere With Durvalumaband Tremelimumab for HCCBoston Scientific CorporationPhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 1 · ClinicalTrials.gov record · Version of 2026-10-01Oct 30 · ClinicalTrials.gov record · Version of 2026-10-30Version of 2026-10-30CONDITIONSCarcinoma, HepatocellularThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionCarcinomaThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseNeoplasms, Glandular and Ep…The registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedNeoplasms by Histologic TypeThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedNeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseAdenocarcinomaThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseLiver NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedDigestive System NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedNeoplasms by SiteThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedDigestive System DiseasesThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseLiver DiseasesThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSDurvalumabEntry “Durvalumab (Imfinzi) immunothe…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTremelimumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
2 versions of the record seen on ClinicalTrials.gov, Oct 1–Oct 30 · changes seen, not judgments
Nov 3DurvalumabClaude Opus 5.5TestedCurrent
Nov 3Tremelimumabmade hereClaude Opus 5.5TestedCurrent
Nov 14Carcinoma, HepatocellularRule based · condition-kind ruleFinest filed termCurrent
Nov 14CarcinomaRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Neoplasms, Glandular and EpithelialRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Neoplasms by Histologic TypeRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14NeoplasmsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14AdenocarcinomaRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Liver NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Digestive System NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Neoplasms by SiteRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Digestive System DiseasesRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Liver DiseasesRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18DurvalumabRule based · role ruleTestedAgrees
As of nowCarcinoma, HepatocellularRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.